Nuo Therapeutics(AURX)
$1.09+0.02 (+1.87%)
AURX
Nuo Therapeutics financials statements
$1.09
At close:+0.02 (+1.87%)
Want to see AURX full AI Analyst Report?
Nuo Therapeutics (AURX) Ratios
12 Followers
Nuo Therapeutics Ratios
AURX's free cash flow for Q2 2026 was $-489.50K. For the 2026 fiscal year, AURX's free cash flow was decreased by $-253.03K and operating cash flow was $-236.47K. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Mar 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.06 | 1.45 | 2.32 | 4.39 | 0.22 |
| Quick Ratio | 0.89 | 1.19 | 2.01 | 3.99 | 0.22 |
| Cash Ratio | 0.42 | 0.49 | 1.38 | 3.42 | 0.22 |
| Solvency Ratio | -0.84 | -3.30 | -3.66 | -3.45 | 0.00 |
| Operating Cash Flow Ratio | -0.66 | -3.86 | -4.70 | -6.17 | -0.02 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | -46.65 | 0.00 |
| Net Current Asset Value | $ -1.42M | $ 165.75K | $ 724.71K | $ 1.78M | $ -522.54K |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.32 | 0.14 | 0.14 | 0.11 | 0.00 |
| Debt-to-Equity Ratio | -0.62 | 0.32 | 0.25 | 0.15 | 0.00 |
| Debt-to-Capital Ratio | -1.66 | 0.24 | 0.20 | 0.13 | 0.00 |
| Long-Term Debt-to-Capital Ratio | -1.10 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | -1.93 | 2.32 | 1.81 | 1.39 | -0.29 |
| Debt Service Coverage Ratio | -2934.96 | 0.00 | -968.70 | -37.96 | 0.00 |
| Interest Coverage Ratio | -3130.16 | 0.00 | -1001.98 | -1578.98 | 0.00 |
| Debt to Market Cap | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.01 | 0.00 | 0.01 | 0.01 | 0.00 |
| Net Debt to EBITDA | -0.02 | 0.05 | 0.22 | 0.55 | 0.00 |
| Profitability Margins | |||||
| Gross Profit Margin | 66.94% | 77.82% | 79.28% | 82.88% | 0.00% |
| EBIT Margin | -75.95% | -180.04% | -520.65% | -2823.73% | 0.00% |
| EBITDA Margin | -71.21% | -172.99% | -503.35% | -2757.73% | 0.00% |
| Operating Profit Margin | -75.95% | -180.04% | -520.65% | -2958.21% | 0.00% |
| Pretax Profit Margin | -75.82% | -170.21% | -521.17% | -2825.60% | 0.00% |
| Net Profit Margin | -75.82% | -170.21% | -521.17% | -2695.14% | 0.00% |
| Continuous Operations Profit Margin | -75.82% | -170.21% | -521.17% | -2825.60% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 95.38% | 100.00% |
| EBT Per EBIT | 99.82% | 94.54% | 100.10% | 95.52% | 100.00% |
| Return on Assets (ROA) | -136.11% | -195.35% | -168.88% | -99.28% | -60.47% |
| Return on Equity (ROE) | 262.63% | -452.34% | -305.20% | -138.06% | 17.35% |
| Return on Capital Employed (ROCE) | -466.58% | -402.23% | -263.29% | -135.70% | 17.35% |
| Return on Invested Capital (ROIC) | -408.69% | -362.56% | -244.70% | -127.43% | 17.35% |
| Return on Tangible Assets | -136.11% | -195.35% | -168.88% | -99.28% | -60.47% |
| Earnings Yield | -2.70% | -3.65% | -13.70% | -5.04% | -2992.77% |
| Efficiency Ratios | |||||
| Receivables Turnover | 5.90 | 5.50 | 2.43 | 1.22 | 0.00 |
| Payables Turnover | 2.51 | 1.38 | 0.32 | 0.05 | 0.00 |
| Inventory Turnover | 5.13 | 2.01 | 0.60 | 0.08 | 0.00 |
| Fixed Asset Turnover | 7.11 | 3.92 | 1.94 | 0.27 | 0.00 |
| Asset Turnover | 1.80 | 1.15 | 0.32 | 0.04 | 0.00 |
| Working Capital Turnover Ratio | 19.68 | 2.37 | 0.42 | 0.15 | 0.00 |
| Cash Conversion Cycle | -12.20 | -16.50 | -384.94 | -2695.53 | 0.00 |
| Days of Sales Outstanding | 61.87 | 66.36 | 150.37 | 300.19 | 0.00 |
| Days of Inventory Outstanding | 71.22 | 181.32 | 606.70 | 4559.27 | 0.00 |
| Days of Payables Outstanding | 145.29 | 264.18 | 1142.02 | 7554.99 | 0.00 |
| Operating Cycle | 133.09 | 247.68 | 757.07 | 4859.46 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.02 | -0.05 | -0.08 | -0.09 | -0.00 |
| Free Cash Flow Per Share | -0.02 | -0.05 | -0.08 | -0.09 | -0.00 |
| Dividend Paid and CapEx Coverage Ratio | -3.15 | -14.40 | -437.30 | -61.78 | 0.00 |
| Capital Expenditure Coverage Ratio | -3.15 | -14.40 | -437.30 | -61.78 | 0.00 |
| Operating Cash Flow Coverage Ratio | -1.45 | -13.59 | -12.39 | -11.06 | 0.00 |
| Operating Cash Flow to Sales Ratio | -0.26 | -1.63 | -5.21 | -33.02 | 0.00 |
| Free Cash Flow Yield | -1.22% | -3.75% | -13.72% | -6.28% | -429.16% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -37.10 | -27.37 | -7.30 | -19.83 | -0.03 |
| Price-to-Sales (P/S) Ratio | 28.13 | 46.58 | 38.03 | 534.54 | 0.00 |
| Price-to-Book (P/B) Ratio | -97.44 | 123.79 | 22.27 | 27.38 | -0.01 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -81.78 | -26.65 | -7.29 | -15.93 | -0.23 |
| Price-to-Operating Cash Flow Ratio | -107.76 | -28.50 | -7.31 | -16.19 | -0.23 |
| Price-to-Earnings Growth (PEG) Ratio | -10.00 | 0.85 | 27.58 | -0.01 | 0.00 |
| Enterprise Value Multiple | -39.52 | -26.88 | -7.34 | -18.83 | 0.00 |
| Enterprise Value | 93.25M | 63.47M | 22.47M | 58.29M | -145.40K |
| EV to EBITDA | -39.52 | -26.88 | -7.34 | -18.83 | 0.00 |
| EV to Sales | 28.14 | 46.50 | 36.92 | 519.25 | 0.00 |
| EV to Free Cash Flow | -81.82 | -26.60 | -7.08 | -15.48 | 11.18 |
| EV to Operating Cash Flow | -107.81 | -28.44 | -7.09 | -15.73 | 11.18 |
| Tangible Book Value Per Share | -0.02 | 0.01 | 0.02 | 0.05 | -0.02 |
| Shareholders’ Equity Per Share | -0.02 | 0.01 | 0.02 | 0.05 | -0.02 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.07 | 0.03 | 0.01 | 0.00 | 0.00 |
| Net Income Per Share | -0.05 | -0.05 | -0.08 | -0.08 | -0.00 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 0.95 | 1.00 |
| Interest Burden | 1.00 | 0.95 | 1.00 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 1.43 | 2.58 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.03 | 0.04 | 0.04 | 0.08 | 0.00 |
| Income Quality | 0.34 | 0.96 | 1.00 | 1.17 | 0.68 |
Currency in USD
